These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25322440)

  • 41. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Seamlessly expanding a randomized phase II trial to phase III.
    Inoue LY; Thall PF; Berry DA
    Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Group sequential multi-arm multi-stage trial design with treatment selection.
    Wu J; Li Y; Zhu L
    Stat Med; 2023 May; 42(10):1480-1491. PubMed ID: 36808736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Group sequential methods for cluster randomization trials with binary outcomes.
    Zou GY; Donner A; Klar N
    Clin Trials; 2005; 2(6):479-87. PubMed ID: 16422308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A case study of modeling and exposure-response prediction for count data.
    Quan H; Mao X; Wei L; Wang L
    J Biopharm Stat; 2014; 24(5):1073-90. PubMed ID: 24914574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls.
    Yuan J; Liu J; Zhu R; Lu Y; Palm U
    J Biopharm Stat; 2019; 29(3):558-573. PubMed ID: 30612514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Pocock approach to sequential meta-analysis of clinical trials.
    Shuster JJ; Neu J
    Res Synth Methods; 2013 Sep; 4(3):269-79. PubMed ID: 24348752
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sequential design of phase II-III cancer trials.
    Lai TL; Lavori PW; Shih MC
    Stat Med; 2012 Aug; 31(18):1944-60. PubMed ID: 22422502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An adaptive two-stage design with treatment selection using the conditional error function approach.
    Wang J
    Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.
    Elm JJ; Palesch YY; Koch GG; Hinson V; Ravina B; Zhao W
    J Biopharm Stat; 2012; 22(4):758-72. PubMed ID: 22651113
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Group sequential designs with robust semiparametric recurrent event models.
    Mütze T; Glimm E; Schmidli H; Friede T
    Stat Methods Med Res; 2019 Aug; 28(8):2385-2403. PubMed ID: 29890892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing temporal agreement between central and local progression-free survival times.
    Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
    Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flexible design of two-stage adaptive procedures for phase III clinical trials.
    Koyama T
    Contemp Clin Trials; 2007 Jul; 28(4):500-13. PubMed ID: 17307399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A microcomputer program for the design and analysis of phase II cancer clinical trials with two group sequential methods, the sequential probability ratio test, and the triangular test.
    Bellissant E; Benichou J; Chastang C
    Comput Biomed Res; 1994 Feb; 27(1):13-26. PubMed ID: 8004938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.